{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:01:37Z","timestamp":1740106897602,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Italian Ministry of Health","award":["GR-2013-02356568","5x1000 Funds 2015","Ricerca Corrente"],"award-info":[{"award-number":["GR-2013-02356568","5x1000 Funds 2015","Ricerca Corrente"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00262-021-02965-w","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T09:02:48Z","timestamp":1621328568000},"page":"3349-3355","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Assessment of interferon-\u03b3 in pleural fluid as a prognostic factor of survival in malignant pleural mesothelioma"],"prefix":"10.1007","volume":"70","author":[{"given":"Beatrice","family":"Dozin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Carbotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Roncella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Dessanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Aldo","family":"Canessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Ferrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4203-2022","authenticated-orcid":false,"given":"Marina","family":"Fabbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"2965_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3322\/caac.21572","volume":"69","author":"M Carbone","year":"2019","unstructured":"Carbone M, Adusumilli PS, Alexander HR et al (2019) Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin 69:402\u2013429. https:\/\/doi.org\/10.3322\/caac.21572","journal-title":"CA Cancer J Clin"},{"key":"2965_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fonc.2020.00187","volume":"10","author":"CJ de Gooijer","year":"2020","unstructured":"de Gooijer CJ, Borm FJ, Scherpereel A, Baas P (2020) Immunotherapy in malignant pleural mesothelioma. Front Oncol 10:187. https:\/\/doi.org\/10.3389\/fonc.2020.00187","journal-title":"Front Oncol"},{"key":"2965_CR3","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","volume":"18","author":"M Maio","year":"2017","unstructured":"Maio M, Scherpereel A, Calabr\u00f2 L et al (2017) Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 18:1261\u20131273. https:\/\/doi.org\/10.1016\/S1470-2045(17)30446-1","journal-title":"Lancet Oncol"},{"key":"2965_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","volume":"20","author":"A Scherpereel","year":"2019","unstructured":"Scherpereel A, Mazieres J, Greillier L et al (2019) Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 20:239\u2013253. https:\/\/doi.org\/10.1016\/S1470-2045(18)30765-4","journal-title":"Lancet Oncol"},{"key":"2965_CR5","doi-asserted-by":"publisher","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","volume":"25","author":"M Okada","year":"2019","unstructured":"Okada M, Kijima T, Aoe K et al (2019) Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, japanese phase ii study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 25:5485\u20135492. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0103","journal-title":"Clin Cancer Res"},{"key":"2965_CR6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","volume":"7","author":"MJ Disselhorst","year":"2019","unstructured":"Disselhorst MJ, Quispel-Janssen J, Lalezari F et al (2019) Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 7:260\u2013270. https:\/\/doi.org\/10.1016\/S2213-2600(18)30420-X","journal-title":"Lancet Respir Med"},{"key":"2965_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","volume":"181","author":"JP Hegmans","year":"2010","unstructured":"Hegmans JP, Veltman JD, Lambers ME et al (2010) Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 181:1383\u20131390. https:\/\/doi.org\/10.1164\/rccm.200909-1465OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2965_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","volume":"24","author":"JGJV Aerts","year":"2018","unstructured":"Aerts JGJV, de Goeje PL, Cornelissen R et al (2018) Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: from mouse to human. Clin Cancer Res 24:766\u2013776. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2522","journal-title":"Clin Cancer Res"},{"key":"2965_CR9","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.201508-1573OC","volume":"193","author":"R Cornelissen","year":"2016","unstructured":"Cornelissen R, Hegmans JPJJ, Maat APWM et al (2016) Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med 193:1023\u20131031. https:\/\/doi.org\/10.1164\/rccm.201508-1573OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2965_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/s0169-5002(00)00217-8","volume":"32","author":"BW Robinson","year":"2001","unstructured":"Robinson BW, Robinson C, Lake RA (2001) Localised spontaneous regression in mesothelioma\u2013possible immunological mechanism. Lung Cancer 32:197\u2013201. https:\/\/doi.org\/10.1016\/s0169-5002(00)00217-8","journal-title":"Lung Cancer"},{"key":"2965_CR11","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","volume":"59","author":"N Yamada","year":"2010","unstructured":"Yamada N, Oizumi S, Kikuchi E et al (2010) CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 59:1543\u20131549. https:\/\/doi.org\/10.1007\/s00262-010-0881-6","journal-title":"Cancer Immunol Immunother"},{"key":"2965_CR12","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.jtcvs.2007.10.026","volume":"135","author":"M Anraku","year":"2008","unstructured":"Anraku M, Cunningham KS, Yun Z et al (2008) Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 135:823\u2013829. https:\/\/doi.org\/10.1016\/j.jtcvs.2007.10.026","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2965_CR13","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.jtho.2019.03.029","volume":"14","author":"IC Salaroglio","year":"2019","unstructured":"Salaroglio IC, Kopecka J, Napoli F et al (2019) Potential diagnostic and prognostic role of microenvironment in malignant pleural mesothelioma. J Thorac Oncol 14:1458\u20131471. https:\/\/doi.org\/10.1016\/j.jtho.2019.03.029","journal-title":"J Thorac Oncol"},{"key":"2965_CR14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L et al (2019) Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun 10:1333. https:\/\/doi.org\/10.1038\/s41467-019-09307-6","journal-title":"Nat Commun"},{"key":"2965_CR15","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1002\/ijc.32363","volume":"145","author":"R Sottile","year":"2019","unstructured":"Sottile R, Tannazi M, Johansson MH et al (2019) NK- and T-cell subsets in malignant mesothelioma patients: baseline pattern and changes in the context of anti-CTLA-4 therapy. Int J Cancer 145:2238\u20132248. https:\/\/doi.org\/10.1002\/ijc.32363","journal-title":"Int J Cancer"},{"key":"2965_CR16","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP (2008) Exploring the full spectrum of macrophage activation. Nat Rev Immunol 8:958\u2013969. https:\/\/doi.org\/10.1038\/nri2448","journal-title":"Nat Rev Immunol"},{"key":"2965_CR17","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.jtho.2016.06.022","volume":"11","author":"A-L Ch\u00e9n\u00e9","year":"2016","unstructured":"Ch\u00e9n\u00e9 A-L, d\u2019Almeida S, Blondy T et al (2016) Pleural effusions from patients with mesothelioma induce recruitment of monocytes and their differentiation into M2 macrophages. J Thorac Oncol 11:1765\u20131773. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.022","journal-title":"J Thorac Oncol"},{"key":"2965_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jtho.2016.06.021","volume":"11","author":"LA Lievense","year":"2016","unstructured":"Lievense LA, Cornelissen R, Bezemer K et al (2016) Pleural effusion of patients with malignant mesothelioma induces macrophage-mediated t cell suppression. J Thorac Oncol 11:1755\u20131764. https:\/\/doi.org\/10.1016\/j.jtho.2016.06.021","journal-title":"J Thorac Oncol"},{"key":"2965_CR19","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3389\/fonc.2019.01366","volume":"9","author":"GJ Chu","year":"2019","unstructured":"Chu GJ, van Zandwijk N, Rasko JEJ (2019) The immune microenvironment in mesothelioma: mechanisms of resistance to immunotherapy. Front Oncol 9:1366. https:\/\/doi.org\/10.3389\/fonc.2019.01366","journal-title":"Front Oncol"},{"key":"2965_CR20","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA et al (2018) Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov 8:1548\u20131565. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0804","journal-title":"Cancer Discov"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02965-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T12:16:13Z","timestamp":1633954573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2965"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02965-w","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"type":"print","value":"0340-7004"},{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The author declares there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The local Ethical Committee (Azienda Sanitaria Locale n.5 La Spezia) approved the study (P.R. 207REG2014). All procedures performed in the study were in accordance with the Declaration of HELSINKI.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided a signed informed consent before enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}